ClinicalTrials.gg
CompletedNCT02351115Updated Apr 20, 2026Results posted

Staccato Alprazolam and Photoparoxysmal Response

A Phase 2 interventional study of A=Placebo and B=Inhaled Alprazolam 0.5 mg in Epilepsy, sponsored by Nova Pneuma Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Nova Pneuma Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Enrollment
525th of 588
5 · median 40
Started
2015
with 37 others
Phase 2
103 of 793
6 open now
Registered
360th of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 525th largest by enrollment of the 588 interventional ones that give a count, is one of 38 that started in 2015, is one of 103 in phase 2, and was the 360th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.

Read the detailed description

The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo. People with photosensitive epilepsy have changes on their electroencephalogram (EEG) when shown flashing lights. Three dose levels of Staccato Alprazolam will be compared to placebo.

This study will also assess the level of sedation of Staccato Alprazolam compared to placebo.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between the ages of 18 to 60 years, inclusive
  • (BMI) ≥18 and ≤35 kg/m2
  • Able to speak, read, and understand English and willing and able to provide written on an IRB-approved form before the initiation of any study procedures
  • A diagnosis and history of a photoparoxysmal response on EEG with or without a diagnosis of epilepsy for which patients are on 0-2 concomitant antiepileptic drugs
  • At least 3 of the EEGs performed during the screen visit must have a reproducible IPS-induced photoparoxysmal response (PPR) on EEG of at least 3 points on a frequency assessment scale in at least one eye condition
  • In otherwise good general health as determined by a complete medical history, physical examination, 12-lead , blood chemistry profile, hematology, and urinalysis
  • Female participants (if of and sexually active) and male participants (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective method throughout the study and for 1 week following the end of the study. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine device (IUD), surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone

Exclusion criteria

Exclusion Criteria:

  • History of non-epileptic seizures (e.g. metabolic, structural, or pseudo-seizures)
  • History of seizure worsening in response to narrow spectrum drugs
  • An active CNS infection, demyelinating disease, degenerative neurological disease or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results
  • Use of more than 2 concomitant AEDs for epilepsy treatment
  • Subjects taking known inhibitors or inducers of , including carbamazepine
  • Subjects with a history of allergic reactions to alprazolam or other benzodiazepines
  • Treatment with an drug within 30 days (or within 5 half-lives of the investigational drug, if >30 days) before Visit 2
  • A history within the past 1 year of drug or alcohol dependence or abuse
  • Positive urine screen for drugs of abuse at Visit 1 - Screening
  • A history of -positivity
  • Female subjects who have a positive pregnancy test at screening or prior to test sessions or are breastfeeding
  • History of acute narrow angle glaucoma, Parkinson's disease, hydrocephalus, or history of significant head trauma
  • Subjects who have a current history of asthma, chronic obstructive lung disease (), or any lung disease associated with bronchospasm
  • Subjects who use medications to treat airways disease, such as asthma or COPD
  • Subjects who have any acute respiratory signs/symptoms (e.g., wheezing)
  • abnormality including (but not limited to) any of the following conduction abnormalities or dysrhythmias: atrial fibrillation, mean (QT interval corrected for heart rate using Fridericia's method) interval >450 msec, ventricular rate \<45 beats/min, second or third degree AV block, left bundle branch block, or evidence of prior myocardial infarction (MI) or acute ischemia
  • Hypotension (systolic blood pressure ≤90 mm Hg, diastolic blood pressure ≤50 mm Hg), or hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥100 mm Hg) measured while seated at screening or baseline
  • Significant hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease and congestive heart failure), endocrine, neurologic (including history of seizures or stroke), or hematologic disease
  • Any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Sequence BEADC

    A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo

    Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo

  • Experimental
    Sequence CDAEB

    A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo

    Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo

  • Experimental
    Sequence DEBAC

    A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo

    Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo

  • Experimental
    Sequence EDBAC

    A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo

    Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo

  • Experimental
    Sequence CABED

    A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo

    Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo

Interventions

  • DrugA=Placebo
  • DrugB=Inhaled Alprazolam 0.5 mg
  • DrugC=Inhaled Alprazolam 1 m
  • DrugD= Inhaled Alprazolam 2 mg
  • DrugE=Placebo
06

What researchers measure

Primary outcomes

  1. Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)

    Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)

    Time frame: SPR was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at: 10 min for alprazolam 2 mg, 1 hour for alprazolam 0.5 and 1 mg and placebo

Secondary outcomes

  1. Maximum Sedation Using Visual Analog Scale (Sedated-Alert)

    Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)

    Time frame: Sedation was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at:: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg, and 4 hours for placebo

  2. Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)

    Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)

    Time frame: Sleepiness was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred: at: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg and placebo

  3. Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)

    Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose

    Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration

  4. Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)

    Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose

    Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration

  5. Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)

    Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose

    Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration

07

Results

Posted Aug 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneBEADCCDAEBDEBACEDBACCABED
Started11111
Completed11111
Not completed00000

Outcome measures

PrimaryMaximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)

Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)

Time frame:
SPR was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at: 10 min for alprazolam 2 mg, 1 hour for alprazolam 0.5 and 1 mg and placebo
Reported as:
Mean · Number of frequency steps
Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)
Number of frequency stepsInhaled PlaceboStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)-0.2 (-1.87 to 1.47)-4.4 (-6.98 to -1.82)-5.2 (-7.85 to -2.55)-4.8 (-7.99 to -1.61)
SecondaryMaximum Sedation Using Visual Analog Scale (Sedated-Alert)

Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)

Time frame:
Sedation was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at:: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg, and 4 hours for placebo
Reported as:
Mean · units on a scale
Maximum Sedation Using Visual Analog Scale (Sedated-Alert)
units on a scaleInhaled PlaceboStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Maximum Sedation Using Visual Analog Scale (Sedated-Alert)-5.3 (-23.84 to 13.34)-58 (-82.77 to -33.23)-67.4 (-87.47 to -47.33)-70.6 (-94.06 to -47.14)
SecondaryMaximum Sedation Using Visual Analog Scale (Sleepy-Awake)

Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)

Time frame:
Sleepiness was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred: at: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg and placebo
Reported as:
Mean · units on a scale
Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)
units on a scaleInhaled PlaceboStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)-9.2 (-26.33 to 7.93)-54 (-72.59 to -35.31)-58.8 (-76.01 to -41.59)-58.8 (-69.4 to -48.2)
SecondaryCorrelation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)

Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose

Time frame:
Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
Reported as:
Mean · correlation coefficient
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)
correlation coefficientStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)-0.454 ± 0.206-0.534 ± 0.286-0.410 ± 0.168
SecondaryCorrelation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)

Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose

Time frame:
Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
Reported as:
Mean · correlation coefficient
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)
correlation coefficientStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)-0.350 ± 0.122-0.567 ± 0.322-0.623 ± 0.388
SecondaryCorrelation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)

Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose

Time frame:
Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
Reported as:
Mean · correlation coefficient
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)
correlation coefficientStaccato Alprazolam, 0.5 mgStaccato Alprazolam, 1 mgStaccato Alprazolam, 2 mg
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)-0.449 ± 0.201-0.582 ± 0.339-0.586 ± 0.343

Adverse events

Collected over Each subject was questioned about adverse events (AEs) at 2 min, 10 min, 30 min, 1 hr, 2 hr, 4 hr, and 6 hr post study drug administration for each study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Placebo0/5 (0%)0/5 (0%)2/5 (40%)
Staccato® Alprazolam, 0.5 mg0/5 (0%)0/5 (0%)2/5 (40%)
Staccato® Alprazolam, 1 mg0/5 (0%)0/5 (0%)3/5 (60%)
Staccato® Alprazolam, 2 mg0/5 (0%)0/5 (0%)4/5 (80%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventInhaled PlaceboStaccato® Alprazolam, 0.5 mgStaccato® Alprazolam, 1 mgStaccato® Alprazolam, 2 mg
DiarrheaGastrointestinal disorders2/50/50/50/5
DysgeusiaGastrointestinal disorders1/52/52/52/5
Oral dysaesthesiaGastrointestinal disorders0/52/50/52/5
SedationNervous system disorders0/50/51/52/5
SomnolenceNervous system disorders1/51/52/52/5
CoughRespiratory, thoracic and mediastinal disorders1/52/51/52/5
Eye irritationEye disorders1/50/50/50/5
Lacrimation increasedEye disorders0/51/51/51/5
Abdominal pain upperGastrointestinal disorders0/51/50/50/5
RetchingGastrointestinal disorders0/50/50/51/5

Baseline characteristics

All subjects treated

Age, Continuous
Age, Continuous(years)BEADC BEADCCDAEBDEBACEDBACCABEDTotal
Mean24 ± 023 ± 027 ± 039 ± 023 ± 027.2 ± 6.80
Sex: Female, Male
Sex: Female, Male(Participants)BEADC BEADCCDAEBDEBACEDBACCABEDTotal
Female111115
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BEADC BEADCCDAEBDEBACEDBACCABEDTotal
Ethnicity — Hispanic or Latino000011
Ethnicity — Not Hispanic or Latino111104
Ethnicity — Unknown or Not Reported000000
Race — Hispanic or Latino000011
Race — Not Hispanic or Latino111104
Race — Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)BEADC BEADCCDAEBDEBACEDBACCABEDTotal
United States111115
08

Study locations

3 sites
  • Consultants in Epilepsy & Neurology, PLLC
    Boise, Idaho, United States
  • New York University Epilepsy Center
    New York, New York, United States
  • University of Pennsylvania - Penn Epilepsy Center
    Philadelphia, Pennsylvania, United States
09

References and documents

Individual participant data

Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within 10 days of request approval

Access criteria: Approval of formal request for access

Data sharing details ↗ · alexza.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2021, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2015
First posted
Jan 30, 2015
Start
Jan 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Aug 10, 2021
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02351115
Lead sponsor
Nova Pneuma Inc.
Collaborators
The Epilepsy Study Consortium
Responsible party
Sponsor
First posted
Jan 30, 2015
Start date
Jan 2015
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Aug 10, 2021
Last update
Apr 20, 2026

Study contacts

J Isojarvi, MD
study chair · Engage Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion